Search

News Trazodone with Extended Release Improves Patient Compliance

Since 2015, the antidepressant trazodone is available in the Czech Republic in a controlled-release formulation. A sufficiently high plasma level for 24 hours without fluctuation allows for administration only once a day, while eliminating side effects.

Source: Depression and Anxiety 20. 5. 2020

News Over 10 Years of Experience with TPO-RA in the Treatment of Immune Thrombocytopenia

Medications from the group of thrombopoietin receptor agonists (TPO-RA) have become an integral part of the therapy for patients with immune thrombocytopenia (ITP) over the past more than 10 years. Their administration represents a new approach compared to the previous, long-established treatment, and has significantly changed the prognosis of the disease in many patients.

Source: Immune Thrombocytopenia 9. 4. 2022

News Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP

What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of patients with immune thrombocytopenia (ITP)? Italian authors conducted a survey using the Delphi method among selected experts to gather answers to this question and recommendations for clinical practice. Here, we briefly summarize the key points of their consensus published last year.

Source: Immune Thrombocytopenia 10. 8. 2022

News Side Effects of Antipsychotics and Patient Preferences in the Treatment of Schizophrenia

Although a number of antipsychotics are currently available, many patients still suffer from unpleasant side effects associated with the treatment of schizophrenia. To determine how individuals with schizophrenia and schizoaffective disorders perceive antipsychotic treatment, a larger survey was conducted in the USA in 2016.

Source: Modern Treatment of Schizophrenia 9. 10. 2023

News Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM

Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy of symptomatic treatment with mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), with the longest follow-up period nearly 2.5 years. For clinical practice, the long-term reduction of left ventricular outflow tract (LVOT) obstruction and good tolerability of the treatment are particularly favorable.

Source: Hypertrophic Cardiomyopathy (HCM) 19. 2. 2024

News L. reuteri DSM 17938 in Infant Nutrition and Its Impact on the Gut Microbiota of Infants Born by Cesarean Section

The work of the Swiss-Greek team published in the Journal of Pediatric Gastroenterology and Nutrition focused on comparing the effect of infant formula containing Lactobacillus reuteri DSM 17938 on the microbiota of children born by cesarean section or vaginal delivery.

Source: GI, colic and microbiome 15. 5. 2020

News Current ASH Guidelines on ITP Management 2019 –⁠ Recommendations for Newly Diagnosed ITP in Children

At the end of 2019, the American Society of Hematology (ASH) published current guidelines for immune thrombocytopenia (ITP), in which a panel of experts attempted to define evidence-based recommendations for the care management of these patients.

Source: Immune Thrombocytopenia 22. 4. 2020

News Efficacy and Safety of Ultrahypofractionated Proton Therapy in the Treatment of Prostate Cancer in Real-World Czech Practice

A team from the Prague Proton Therapy Center, led by Associate Professor Jiří Kubeš, published a study with nearly 300 patients in the prestigious International Journal of Radiation Oncology, Biology, Physics. It demonstrates the significant efficacy and low toxicity of the ultrahypofractionated proton therapy regimen in patients with prostate cancer. We summarize the main results.

Source: Proton Radiotherapy 5. 4. 2023

News Does Peritoneal Dialysis Have Its Place Even in Acute Cases?

In patients who urgently need to replace kidney function, hemodialysis traditionally played the role of the gold standard. Can peritoneal dialysis fully replace it?

Source: Chronic Kidney Disease 8. 6. 2021

News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment

The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.

Source: Oncological Treatment 15. 10. 2021

News INFOGRAPHIC: Diagnostic Algorithm for Cardiac Amyloidosis

What examinations are needed when cardiac amyloidosis is suspected? Which tests can distinguish transthyretin amyloidosis from systemic disease caused by immunoglobulin light chains? We bring you a clear diagnostic scheme according to the recommendations of the European Society of Cardiology (ESC). .

Source: Amyloidosis 27. 2. 2023

News The Immune System in the Pathophysiology of ITP

From the perspective of the pathophysiology of immune thrombocytopenia (ITP), it appears that the etiology of this disease is very complex and involves both antibody and cellular immunity.

Source: Immune Thrombocytopenia 9. 4. 2022

News How to Prevent and Treat Thromboembolic Disease in Cancer Patients

Malignancy is one of the risk factors for the development of thromboembolic disease (TED). Venous thromboembolism is considered the second most common cause of death in cancer patients, with the top cause being the cancer itself. Therefore, optimal treatment and timely prevention of these complications is very important.

Source: Thromboprophylaxis 6. 3. 2021

News After 20 years, a new treatment option for primary biliary cholangitis arrives

Primary biliary cholangitis (PBC), formerly known as cirrhosis, is a rare disease with a negative impact on prognosis and quality of life. While ursodeoxycholic acid (UDCA) has been essentially the only treatment option for PBC so far, in 2016, the European Medicines Agency (EMA) approved obeticholic acid as a second-line option. Since 2019, this medication has been available and fully covered by health insurance in 11 selected centers in the Czech Republic.

Source: Primary Biliary Cholangitis 10. 6. 2020

News Diabetic Cardiovascular Autonomic Neuropathy: How to Detect This Serious Diagnosis and Why Is It Dangerous?

Diabetic autonomic neuropathy can affect various organ systems. Cardiovascular autonomic neuropathy is one of its most severe forms with a significant impact on patient morbidity and mortality. How can it be detected in clinical practice?

Source: Diabetes 27. 1. 2022